Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SR13668

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

SRI International

Drug class:

EGFR inhibitor, AKT inhibitor, NF-κB inhibitor

Related drugs:

‹

omtriptolide (1)

ascorbic acid/menadione (0)

efprezimod alfa (0)

piceatannol (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

capivasertib (37)

pexidartinib (6)

enzastaurin (3)

inhibitors of the PI3K/AKT/mTOR pathway (0)

BAY-61-3606 (1)

sodium metaarsenite (1)

omtriptolide (1)

ascorbic acid/menadione (0)

efprezimod alfa (0)

piceatannol (0)

›